Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Melanoma 21Carcinoma, Renal Cell 21Neoplasms 8Lung Neoplasms 8Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Neoplasm Metastasis 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Stomach Neoplasms 5Rectal Neoplasms 5Hodgkin Disease 5Adenocarcinoma Of Esophagus 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Nasopharyngeal Carcinoma 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Colonic Neoplasms 3Brain Neoplasms 3Anus Neoplasms 3

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 7Cisplatin 6pembrolizumab 4durvalumab 4Platinum 4Carboplatin 41,2-diaminocyclohexaneplatinum II citrate 4cemiplimab 3Radiation 3Paclitaxel 3Cetuximab 3Biopsy 3(225)Ac-DOTA-c(RGDyK) 3cabozantinib 2atezolizumab 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Pemetrexed 2Nivolumab 2Immunoglobulin G 2Docetaxel 2Disulfides 2ALT-803 2130-nm albumin-bound paclitaxel 2zipalertinib 1repotrectinib 1poly ICLC 1ipatasertib 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × Nivolumab × 30 days × Clear all
NCT05136196 2026-06-05

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

National Cancer Institute (NCI)

Phase 2 Recruiting
150 enrolled
DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06463665 2026-06-04

VIRO-25

Genelux Corporation

Phase 2 Recruiting
142 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡